Monitoring of cancer patients undergoing active or passive immunotherapy

Journal of Immunotherapy

Volumn 20, Issue 1, 1997, Pages 1-14

  Salgaller, Michael L ^a  

^a Northwest Biotherapeutics LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSTIMULATION; LYMPHOCYTE DIFFERENTIATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CYTOTOXICITY TESTS, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; MONITORING, IMMUNOLOGIC; NEOPLASMS;

EID: 0031436611     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199701000-00001     Document Type: Article

References (113)

1. Boon T. The era of peptide vaccines [Abstract]. Cancer Vac-cines, Cancer Vaccines Meeting, New York City, October 7-9, 1996. New York: Cancer Research Institute, 1996.
2. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science 1991;254:1643.
3. Gaugler B, van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-30.
4. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
5. van den Eynde B, Peeters O, De Backer O, et al. A new family of gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
6. Brandle D, Brasseur F, Weynants P, Boon T, van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphoyctes on a human renal cell carcinoma. J Exp Med 1996;183:2501-8.
7. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3.
8. Ressing ME, Sette A, Brandt RMP, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A2*0201-binding peptides. J Immunol 1995;154:5934-43.
9. Chen BP, DeMars R, Sondel PM. Presentation of soluble antigen to human T cells by products of multiple HLA-linked loci: analysis of antigen presentation by a panel of cloned, autologous, HLA-mutant Epstein-Barr virus-transformed lymphoblastoid cell lines. Hum Immunol 1987;18:75-91.
10. Murphy GP, Ragde H, Kenny G, et al. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 1995; 15:1473-80.
11. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-1811.
12. Murphy GP, Tino WT, Homes EH, et al. Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate 1996;28:266-71.
13. Wright SD Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28.
14. Coulie PG, Brichard V, Van Pel A, et al. A new gene encoding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
15. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
16. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanoma. J Exp Med 1993; 178:489-95.
17. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
18. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
19. Wang R, Robbins PF, Kawakami Y, Kang X, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799-804.
20. Robbins PF, El-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-50.
21. Livingston PO, Wong GYC, Adluri S, et al. Improved survival in stage II melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
22. Robbins PF, El-Gamil M, Li YF, et al. A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
23. ras protein by immunization in vivo with the oncogenic protein. J Immunother 1993;14:110-4.
24. Cheever MA, Chen W, Disis ML, Takahashi M, Peace DJ. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. Ann NY Acad Sci 1993;690:101-12.
25. + cytotoxic T-cells. Cancer Res 1993;53:3257-61.
26. Stuber G, Leder GH, Storkus WJ, et al. Identification of wild-type and mutant p53 peptide binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol 1994;24:765-8.
27. Rosenberg SA. The development of new cancer therapies based on the molecular identification of cancer regression genes. Cancer J 1995;1:90-100.
28. Pardoll D. Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 1995;13:399-415.
29. Slingluff CL Jr. Tumor antigens and tumor vaccines: peptides as immunogens. Semin Surg Oncol 1996;12:446-53.
30. Bear HD, Hamad GG, Kostuchenko PJ. Biologic therapy of melanoma with cytokines and lymphocytes. Semin Surg Oncol 1996;12:436-45.
31. Celis E, Sette A, Grey HM. Epitope selection and development of peptide based vaccines to treat cancer. Semin Cancer Biol 1995;6:329-39.
32. Irvine KR, Restifo NP. The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol 1995; 6:337-47.
33. Blachere NE, Srivastava PK. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 1995;6:349-55.
34. Livingston PO. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 1995;6:357-66.
35. McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 1995;6:375-85.
36. Cerottini J, von Fliedner V, Boon T. Recognition of tumor-associated antigens by T lymphocytes: from basic concepts to new approaches. Ann Oncol 1992;3:11-6.
37. Hellstrom KE, Hellstrom I, DeVita V Jr, Heilman S, Rosenberg SA, eds. Principles of tumor immunity: tumor antigens. In: Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:35-52.
38. Boon T, Cerottini J, van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 1994;12:337-65.
39. van den Eynde B, Brichard VG. New tumor antigens recognized by T cells. Curr Opin Immunol 1995;7:674-81.
40. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology, 2nd ed. Philadelphia: WB Saunders, 1994.
41. Schwartzentruber DJ, Horn SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-83.
42. Salgaller ML, Marineóla FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
43. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2:52-8.
44. Bakker ABH, Schreurs MWJ, de Boer AJ, et al. Melanocyte lineage-specific antigen gplOO is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-9.
45. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
46. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gplOO modified at HLÄ-Ä*0201 binding residues. J Immunol 1996;157:2539-48.
47. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MÄRT-1/Melan A. Cancer J Sci Amer (in press).
48. Barth A, Hoon DSB, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994;54:3342-5.
49. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
50. Robbins P, Hand P, Salgaller M, Poole D, Schlom J. Evaluation of human CEA-transduced and non-transduced tumors as potential targets for anti-CEA therapies. Cancer Immunol Immunother 1993;36:65-75.
51. Fritsche R, Mach J. Isolation of characterization of carcinoembryonic antigen (CEA) extracted from normal human colon mucosa. Immunochemistry 1977;14:119-27.
52. Chang AE, Yoshizawa H, Sakai K, et al. Clinical observations on adoptive immunotherapy with vaccine-primed T-lympho-cytes secondarily sensitized to tumor in vitro. Cancer Res 1993;53:1043-50.
53. Berd D, Maguire Jr, M. Mastrangelo MJ. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 1993;690:147-52.
54. Stover CK, de la Cruz VF, Fuerst TR, et al. New use of BCG for recombinant vaccines. Nature 1991;351:456-60.
55. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune response against autologous tumor in humans bearing malignant melanoma. J Immunol 1987;138:989.
56. Rosenberg SA, Packard B, Aebersold P, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;319:1676-80.
57. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Can Inst 1994;86:1159-66.
58. Patel BT, Lutz MB, Schlag P, Schirrmacher V. An analysis of autologous T-cell anti-tumor responses in colon-carcinoma patients following active specific immunization (ASI). Int J Cancer 1992;51:878-85.
59. Oka M, Hazama S, Yoshino S, et al. Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results. Cancer Immunol Immunother 1994;38:194-200.
60. Schomburg A, Menzel T, Körfer A, et al. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant IL-2. Nat Immun 1992;11:133-43.
61. Jones RC, Kelley M, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996;3:437-45.
62. Morton DL, Foshag LJ, Hoon DSB. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
63. McCune CC, O’Donnell RW, Marquis DM, Sahasrabudhe PM. Renal-cell carcinoma treated by vaccines for active specific immunotherapy: a correlation of survival with skin testing by autologous tumor. Cancer Immunol Immunother 1990;32:62-6.
64. Bystryn J, Oratz R, Roses D, et al. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992;69:1157-64.
65. Berd D, Maguire MC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67.
66. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guerin. Cancer 1996; 77:2560-6.
67. Sato T, Maguire MC Jr, Mastrangelo MJ, Berd D. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin Immun Immunopath 1995;74:35-43.
68. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Ann Rev Immunol 1993;11:403-50.
69. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
70. Mizoguchi H, O’Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.
71. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610-2.
72. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-6.
73. Zea AH, Curti BD, Longo DL, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327-35.
74. Weidmann E, Trucco M, Whiteside TL. Relevance of the T cell receptor for immunotherapy of cancer. Cancer Immunol Immunother 1994;39:1-14.
75. Rabinowich H, Banks M, Reichert TE, et al. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996;2:1263-74.
76. Horn SS, Schwartzentruber DJ, Rosenberg SA, Topalian SL. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother 1993;13:18-30.
77. Kishimoto T. The biology of interleukin 6. Blood 1990; 14:1-10.
78. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22.
79. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multi-institutional study. J Clin Oncol 1996;14:1697-703.
80. Gratma JW, Schmitz PIM, Goey SH, et al. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFNa and autologous IL-2-activated lymphocytes). Int J Cancer 1996; 65:152-60.
81. Blay JY, Favrot MC, Negrier S, et al. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res 1990;50:2371-4.
82. Maffezzini M, Simonato A, Fortis C. Salvage immunotherapy with subcutaneous recombinant interleukins (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 1996; 28:282-6.
83. Sato T, McCue P, Masuoka K, et al. Interleukin 10 production by human melanoma. Clin Cancer Res 1996;2:1383-90.
84. Reynolds SA, Oratz R, Shapiro RL et al. A polyvalent melanoma vaccine induced MAGE-3 and MART-l/Melan-A specific CD8+ T cell responses that correlate with clinical outcome [Abstract]. Cancer Vaccines, Cancer Vaccines Meeting, New York City, October 7-9, 1996. New York: Cancer Research Institute, 1996.
85. Rosenberg SA. The development of cancer vaccines based on the genes encoding melanoma antigens [Abstract], Cancer Vaccines, Cancer Vaccines Meeting, New York City, October 7-9, 1996. New York: Cancer Research Institute, 1996.
86. Herr W, Scheider J, Lohse AW, Meyer Zum Biischenfelde K, Wolfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor a in response to HLA-A2.1-binding and viral peptide antigens. J Immunol Methods 1996;191:131-42.
87. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disi-alogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix. J Cell Biol 1986;102:688-96.
88. Chapman PB, Lonberg M, Houghton AN. Light chain variants of an IgG3 anti-GD3 mononuclear antibody and the relationship between avidity, effector functions, tumor targeting, and antitumor activity. Cancer Res 1990;50:1503-9.
89. Miller K, Abeles G, Oratz R, et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1995; 75:495-502.
90. Hoon DSB, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995;154:730-7.
91. McCaffrey M, Yao T, Williams L, et al. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 1996; 2:679-86.
92. Mascart-Lemone F, Gerard M, Libin M, et al. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J Infect Dis 1995;172:1253-60.
93. McFarland EJ, Harding PA, Luckey D, et al. High frequency of gagand envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection. J Infect Dis 1994;170:766-74.
94. Cheever MA, Disis ML, Bernhard H, et al. Immunity to oncogenic proteins. Immunol Rev 1995;145:33-59.
95. Coulie PG, Somville M, Lehmann F, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992; 50:289-97.
96. Mazzocchi A, Belli F, Mascheroni L, et al. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer 1994;58:330-9.
97. Fleuren GJ, Gorter A, Kuppen PJK, Litvinov S, Warnaar SO. Tumor heterogeneity and immunotherapy of cancer. Immunol Rev 1995;145:91-122.
98. Ryser J, MacDonald HR. Limiting dilution analysis of alloan-tigen-reactive T lymphocytes. J Immunol 1979;122:1691-6.
99. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J Immunol 1991; 126: 1614-9.
100. Anichini A, Fossati G, Parmiani G. Clonal analysis of the cytolytic T-cell response to human tumors. Immunol Today 1987;8:385-9.
101. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
102. Yannelli JR, McConnell S, Parker L, et al. Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: comparison of functional reactivity and melanoma antigen recognition. J Immunother 1996;18:263-71.
103. Van Oers MHJ, Pinkster J, Zeijlemaker WP. Quantification of antigen-reactive cells among human T lymphocytes. Eur J Immunol 1978;8:477-84.
104. Romero, P. Monitoring antigen-specific cytolytic T lymphocyte responses in melanoma patients [Abstract]. Cancer Vaccines, Cancer Vaccines Meeting, New York City, October 7-9, 1996. New York: Cancer Research Institute, 1996.
105. Mitchell MS, Harel W, Kan-Mitchell J, et al. Active specific immunotherapy of melanoma with allogenic cell lysates. Ann NY Acad Sci 1993;690:153-66.
106. Coulie PG, Ikeda H, Moretta A, Boon T. Tumor specific T-cell responses against HLA-loss variants [Abstract]. Cancer Vaccines, Cancer Vaccines Meeting, New York City, October 7-9, 1996. New York: Cancer Research Institute, 1996.
107. Oksenberg JR, Stewart S, Begovich AB. Limited heterogeneity of rearranged T-cell receptor Va transcripts in brains of multiple sclerosis patients. Nature 1990;345:344-8.
108. Weidmann E, Logan TF, Yasumura S, et al. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res 1993;53:4745-9.
109. Salvi S, Segalla F, Rao S, et al. Overexpression of the T-cell receptor b-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res 1995; 55:3374-9.
110. Sensi M, Salvi S, Chiara C, et al. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 1993;178:1231-46.
111. Parmiani G, Sensi M, Berd D. Oligoclonal expansion of T cells in vaccinated melanoma patients [Abstract]. Cancer Vaccines, Cancer Vaccines Meeting, New York City, October 7-9, 1996. New York: Cancer Research Institute, 1996.
112. Kan-Mitchell J, Huang X, Steinman L, et al. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother 1993;37:15-25.
113. Nishimura MI, Kawakami Y, Charmley P, et al. T-cell receptor repertoire in tumor-infiltrating lymphocytes: analysis of melanoma-specific long-term lines. J Immunother 1994; 16:85-94.